Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Paulo Bergerot
Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Spotlight on Cabozantinib for Previously Untreated Advanced Renal Cell Carcinoma: Evidence to Date
Cancer Management and Research
Oncology
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma
Biologics: Targets and Therapy
Oncology
Immunology
Gastroenterology
Pharmacology
Rheumatology
Allergy
Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma in Adults Following Prior Vascular Endothelial Growth Factor Targeted Therapy: Clinical Trial Evidence and Experience
Therapeutic Advances in Urology
Urology
Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
Cancers
Cancer Research
Oncology
Potential Roles for PD‐1 and Cabozantinib in Patients With Metastatic Non‐Clear Cell Renal Cell Carcinoma
Oncologist
Cancer Research
Medicine
Oncology
Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Future Perspectives for Personalized Immunotherapy in Renal Cell Carcinoma
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
Cancer Research and Treatment
Cancer Research
Oncology
